SCHEMBL5149253

SCHEMBL5149253

Cc1csc(-c2nc(-c3ccc(=O)n(C(C)C)n3)c(-c3ccccc3)nc2N)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.39
ADORA2A P29274 5/20 0.35
ADORA1 P30542 4/20 0.35
FGFR1 P11362 2/20 0.34
FGFR2 P21802 2/20 0.34
FGFR3 P22607 2/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
P2RY6 Q15077 1/20 0.33
TACR3 P29371 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33
PDE10A Q9Y233 1/20 0.33
POLB P06746 1/20 0.32
TP53 P04637 1/20 0.32
CYP2E1 P05181 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149204 0.91 RAB9A (0.38) ADORA2AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL5147958 0.86 ADORA2A (0.39) ADORA2AADORA1FGFR1FGFR2FGFR3
SCHEMBL6538765 0.85 MET (0.40) METADORA2AADORA1KDM4EALDH1A1
SCHEMBL5149086 0.83 ADORA2A (0.36) ADORA2AADORA1FGFR1FGFR2FGFR3
SCHEMBL5149110 0.82 PDE1A (0.41) ADORA2AADORA1FGFR1FGFR2FGFR3
SCHEMBL5149235 0.82 ADORA2A (0.39) ADORA2AADORA1FGFR1FGFR2FGFR3
SCHEMBL5154867 0.82 ALDH1A1 (0.40) ADORA2AADORA1KDM4EALDH1A1HPGD
SCHEMBL5149057 0.81 TP53 (0.36) ADORA2AADORA1FGFR1FGFR2FGFR3
Iodide SCHEMBL5150934 0.79 ADORA2A (0.35) ADORA2AADORA1FGFR1FGFR2FGFR3
SCHEMBL5148960 0.79 POLB (0.39) ADORA2AFGFR1FGFR2FGFR3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 MET 1668/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.